News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major market-moving news published in the past hour.
  • No significant economic data releases or revisions were reported this hour.
  • No central bank statements, policy moves, or scheduled rate decisions occurred.
  • No major geopolitical incidents or developments reported in the last hour.
  • Corporate headlines and earnings activity were quiet this hour.
  • Light news flow suggests limited direction and likely rangebound markets until new catalysts emerge.

Latest Articles

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

Quantum BioPharma's licensee, Unbuzzd Wellness Inc., has appointed Michael Zapolin as CEO with plans to finance and list the company on a stock exchange as well as execute a nationwide commercial marketing and product rollout in the U.S. Unbuzzd is a clinically validated beverage that accelerates alcohol metabolism, restores mental clarity, and red…

Diginex Consolidates Group-Wide Expertise and Launches Sustainability Science & Intelligence Initiative to Accelerate Product Innovation and Drive Measurable Client Outcomes

Diginex Consolidates Group-Wide Expertise and Launches Sustainability Science & Intelligence Initiative to Accelerate Product Innovation and Drive Measurable Client Outcomes

Diginex Limited, a Nasdaq-listed RegTech company specializing in ESG and sustainability solutions, has launched a new Group-wide Subject Matter Expertise (SME) initiative. This effort consolidates the company's scientific, regulatory, and methodological expertise across its product and advisory services to drive product innovation and deliver measu…

Dillard’s Offers Exclusive Southern Living Christmas Cookbook

Dillard’s Offers Exclusive Southern Living Christmas Cookbook

Dillard's, a leading US fashion retailer, has released the Southern Living Christmas Cookbook exclusively in its stores and online as part of its 32nd annual fundraiser for Ronald McDonald House. Profits from cookbook sales will benefit select Ronald McDonald House chapters across the US, continuing Dillard's long-standing commitment to charitable …

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting

Annexon, Inc. announced presentations highlighting patient baseline characteristics and Phase 2 vision protection findings from the ARCHER program for their investigational neuroprotective drug vonaprument in Geographic Atrophy (GA). The ongoing Phase 3 ARCHER II trial aims to replicate Phase 2 positive vision outcomes, with primary endpoint result…

ZenaTech’s ZenaDrone Advances Defense-Focused Quantum Navigation System for GPS-Denied Operations to Drone Testing Phase

ZenaTech’s ZenaDrone Advances Defense-Focused Quantum Navigation System for GPS-Denied Operations to Drone Testing Phase

ZenaTech's drone subsidiary ZenaDrone has entered the testing phase for its defense-focused quantum navigation system, designed to enable reliable drone operation in GPS-denied and satellite-compromised environments. The system aims to provide secure, redundantly layered navigation using quantum inertial sensing combined with AI path correction. In…

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

Tvardi Therapeutics announced new preclinical data showing that their oral STAT3 inhibitors, including next-generation TTI-109 and first-generation TTI-101, achieve high colon exposure, modulate multiple pathogenic pathways in ulcerative colitis (UC), and prevent colorectal cancer development in models. The data support advancing TTI-109 into clini…

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

Nuvectis Pharma announced that their drug candidate NXP200, an oral BRAF inhibitor targeting BRAF V600-mutant high-grade glioma, has been granted Breakthrough Therapy Designation by China's Center for Drug Evaluation. This designation highlights the promising clinical activity of NXP200 for patients with recurrent or progressive brain tumors. The c…

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026

Lisata Therapeutics, through its subsidiary Marea Therapeutics, announced a late-breaking presentation of Phase 2b clinical data for MAR001, a novel monoclonal antibody targeting ANGPTL4 to treat elevated triglycerides, at the American Heart Association Scientific Sessions 2026. MAR001 aims to reduce triglycerides and improve cardiometabolic health…

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

Elicio Therapeutics announced that new pre-specified analyses from its Phase 2 AMPLIFY-7P study of ELI-002 7P, an immunotherapy targeting KRAS-driven pancreatic cancer, will be presented at ESMO Congress 2026. While the study did not meet its primary endpoint, the additional data provide valuable insights to refine the Phase 3 development strategy …

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

Absci Corporation announced plans for a global, multi-center Phase 2 STORYLINE clinical trial to evaluate the efficacy and safety of ABS-201, an AI-designed anti-prolactin receptor antibody, for treating moderate to severe endometriosis-associated pain. The double-blind, placebo-controlled trial is planned to start in mid-2027, enrolling about 150 …

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

Milestone Pharmaceuticals has enrolled the first patient in Canada for the ReVeRA-301 Phase 3 pivotal trial evaluating their FDA-approved etripamil nasal spray, CARDAMYST, for treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR). This multinational trial aims to enroll 150 patients to assess the efficacy of self-administered etri…

Cronos Hosts 2026 Investor Day

Cronos Hosts 2026 Investor Day

Cronos Group Inc., a global cannabis company, held its first Investor Day at its Kingsville location showcasing its commitment to research, development, and innovation through its diverse international cannabis brands. The event was webcast with presentations made available to investors.

VisionWave Holdings Receives $20 Million Purchase Order for 200 STRATUM VARAN Unmanned Ground Vehicles, Subject to Conditions

VisionWave Holdings Receives $20 Million Purchase Order for 200 STRATUM VARAN Unmanned Ground Vehicles, Subject to Conditions

VisionWave Holdings, Inc. disclosed a purchase order valued at $20 million from Metal Machinery Components Trading FZCO for 200 STRATUM VARAN unmanned ground vehicles. The order's execution is contingent upon multiple conditions, including advance payment, financing proof, regulatory approvals, export licenses, and compliance reviews. Delivery is p…

Terra Innovatum Welcomes Italy’s Historic Return to Nuclear Energy

Terra Innovatum Welcomes Italy’s Historic Return to Nuclear Energy

Terra Innovatum, a Nasdaq-listed company developing the SOLO™ Micro-Modular Reactor, applauds Italy's parliamentary approval of legislation restoring nuclear energy use, creating a new market for advanced nuclear technologies. The legislation supports sustainable nuclear power including small modular reactors, strengthening energy security and deca…

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Nexentis Technologies Inc. has appointed Professor Dan T. Major to the Scientific Advisory Board of its wholly owned subsidiary, MitoCareX Bio Ltd. Prof. Major, an expert in computational chemistry and in silico drug discovery, will advise MitoCareX as it expands its computational drug discovery capabilities to enhance prioritization of its researc…

Sky Quarry Restarts Nevada's Only Crude Oil Refinery

Sky Quarry Restarts Nevada's Only Crude Oil Refinery

Sky Quarry Inc. announced the restart of its Eagle Springs Refinery in Nevada following approval of an air permit by the Nevada Division of Environmental Protection. The refinery, operated by Sky Quarry's subsidiary Foreland Refining Corporation, has a capacity of approximately 5,000 barrels per day. The company completed $300,000 in upgrades and p…

Ziggo Deleveraging Tightens Liberty Global's 2027 Value-Unlock Thesis

Ziggo Deleveraging Tightens Liberty Global's 2027 Value-Unlock Thesis

Liberty Global's operating units have steady cash generation and a recent move by Ziggo to accelerate deleveraging meaningfully reduces execution risk for a 2027 value-unlock event. At $12.41 the shares trade below book and well under the 2026 peak; this trade targets $20 while limiting downside to $10.20 if the macro or integration story derails.